Please login to the form below

Not currently logged in
Email:
Password:

Correction: Prexige suspended in UK, Germany and Austria

PMLive news article correction: Prexige suspended in UK, Germany and Austria

We would like to correct an article which appeared in the December 2007 issue of Pharmaceutical Marketing referring to the suspension of the arthritis drug Prexige (lumiracoxib).

In this article, we referred to this being a Bayer product; this is not the case. We would like to apologise to Bayer for our mistake and have corrected the story online.

The corrected story can be found here

11th December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics